<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02391636</url>
  </required_header>
  <id_info>
    <org_study_id>1</org_study_id>
    <nct_id>NCT02391636</nct_id>
  </id_info>
  <brief_title>Carbetocin and Oxytocin in Elective Caesarean Section With High Risk of Postpartum Hemorrhage</brief_title>
  <official_title>Comparison Between Carbetocin and Oxytocin in Elective Caesarean Section With High Risk of Postpartum Hemorrhage: A Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ghamra Military Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ain Shams Maternity Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Ghamra Military Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Double blinded randomized controlled study
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Women will be randomized into two groups using COMPUTER-GENERATED RANDOM NUMBER LIST.

      264 dark colored envelops will be serially numbered containing the corresponding letter of
      the corresponding drug that will be used.

      Group C: 132 women in the carbetocin group will receive a bolus of 100 μg intravenous
      injection at delivery of the anterior shoulder.

      Group O: 132 women in the oxytocin group will receive 5 IU of oxytocin by slow intravenous
      injection at delivery of the anterior shoulder.

        -  All patients will receive general anaesthesia.

        -  Operation will be carried out by a three year registrar (at least).

        -  Uterus will be repaired in situ. Primary endpoint: is the amount of blood loss.

        -  Blood loss will be estimated using the change in Hb% and hematocrit, the actual blood
           loss will be calculated using the following equation:

        -  The actual blood loss equals the estimated blood volume X difference between the initial
           hematocrit and the final hematocrit / the initial hematocrit

      Secondary endpoints include:

        1. The need for additional uterotonic medication after carbetocin or oxytocin
           administration.

           - Uterine tone and Uterine fundus level (with respect to the umbilical point, UP) will
           be monitored during CS, at the end of CS, 2 hours, 12 hours and 24 hours after delivery

           - Additional uterotonic drugs, needed if sufficient uterine tone is not achieved within
           5 minutes of oxytocin or carbetocin administration, will include: i. Ergometrine 0.5 mg
           by slow intravenous injection. ii. Misopristol 1000 micrograms rectally.

        2. The need for blood transfusion or operative interventions related to PPH

           - The need for blood transfusion or operative intervention (B-Lynch sutures, uterine
           artery ligation, internal iliac artery ligation, Hysterectomy) will be considered.

        3. The change in hemoglobin and hematocrit post versus pre CS

           - The drop in hemoglobin level and hematocrit will be evaluated by comparing the
           hemoglobin concentration on admission and 24 hours after delivery.

        4. The hemodynamic adverse effects and the cost-benefit of both drugs.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2015</start_date>
  <completion_date type="Actual">December 2016</completion_date>
  <primary_completion_date type="Actual">September 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>amount of blood loss</measure>
    <time_frame>24 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>need for another uterotonic medication</measure>
    <time_frame>5 minutes</time_frame>
    <description>after administration of Carbetocin or Oxytocin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>need for blood transfusion or operative intervention</measure>
    <time_frame>during surgery</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">264</enrollment>
  <condition>Postpartum Hemorrhage</condition>
  <arm_group>
    <arm_group_label>Carbetocin arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>100 μg intravenous injection at delivery of the anterior shoulder</description>
  </arm_group>
  <arm_group>
    <arm_group_label>oxytocin arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>5 IU intravenous injection at delivery of the anterior shoulder</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carbetocin</intervention_name>
    <description>at delivery of anterior shoulder</description>
    <arm_group_label>Carbetocin arm</arm_group_label>
    <other_name>Pabal</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxytocin</intervention_name>
    <description>at delivery of anterior shoulder</description>
    <arm_group_label>oxytocin arm</arm_group_label>
    <other_name>Syntocinon</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Multiple pregnancy

          -  Presence of uterine fibroid

          -  Previous Myomectomy

          -  Presence of placenta previa

          -  Past History of PPH

          -  Fetal Macrosomia

          -  Polyhydramnios

        Exclusion Criteria:

          -  Hypertension

          -  Preeclampsia

          -  Cardiac, Renal, Liver diseases

          -  Epilepsy

          -  History of hypersensitivity to Carbetocin
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maged M El.Sherif</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ghamra Military Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ghamra Military Hospital</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 17, 2015</study_first_submitted>
  <study_first_submitted_qc>March 17, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 18, 2015</study_first_posted>
  <last_update_submitted>January 24, 2017</last_update_submitted>
  <last_update_submitted_qc>January 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 25, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ghamra Military Hospital</investigator_affiliation>
    <investigator_full_name>Maged El.Sherif</investigator_full_name>
    <investigator_title>Registrar of OB/GYN</investigator_title>
  </responsible_party>
  <keyword>Postpartum Hemorrhage</keyword>
  <keyword>carbetocin</keyword>
  <keyword>oxytocin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Postpartum Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxytocin</mesh_term>
    <mesh_term>Carbetocin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

